This article is more than 5 years old. Information may no longer be current.

Intravitreal anti-VEGF before vitrectomy for diabetic retinopathy improves long-term outcomes

Eur J Ophthalmol. 2009;19:848-852.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

An intravitreal injection of bevacizumab before planned pars plana vitrectomy for complications from proliferative diabetic retinopathy may be beneficial for long-term outcomes.

In a study of 40 eyes of 40 patients randomly assigned to receive either an injection of Avastin (bevacizumab, Genentech) 3 to 5 days before surgery or no injection before surgery, results were similar in the immediate postoperative period. Postoperative visual acuity improved in both groups and did not differ at 3 months.

However, after a mean 7 months, the 22 patients in the injected group had a mean visual acuity of 1.1 logMAR compared with 1.4 logMAR in the non-injected group (P = .006). Surgical time was shorter in the injected group than in the non-injected group (mean 62 minutes vs. mean 95.5 minutes), and the injected group required fewer endodiathermy applications and backflush cannula applications.